Detecting cervical cancer using menstrual blood biomarkers
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood
This study is testing if a biomarker in menstrual blood can help women find out if they have pre-cervical or cervical cancer without needing invasive procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | WomenX Biotech Limited Industry-sponsored |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06261879 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of ACTN4, a biomarker found in menstrual blood, for the non-invasive detection of pre-cervical and cervical cancer. Participants will undergo a briefing session, complete a health questionnaire, and provide menstrual blood samples for analysis. If ACTN4 is not effective, the study will explore other potential biomarkers. The trial will compare results from women with cervical conditions to those without to determine the sensitivity and specificity of the detection method.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 to 65 who have menstruation and have had sexual intercourse.
Not a fit: Patients with visible signs of gynecological infections or those currently taking medication may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive and accessible method for early detection of cervical cancer.
How similar studies have performed: While the approach of using menstrual blood for cancer detection is innovative, similar studies have shown promise in exploring non-invasive biomarkers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female aged between 18 to 65 * Have menstruation * Had sex before * Can read and write Chinese/ English * Without taking any medication (Except nutritional supplements, traditional Chinese medicine, and health care products etc.) Exclusion Criteria: * Subjects who used medication will be excluded from the sample collection. Moreover, subjects with visible signs of gynarcological infections (e.g. gonorrhea, trichomonas vaginalis) or suffered an HIV/ hepatitis B virus (HBV)-infection will be excluded.
Where this trial is running
Hong Kong
- WomenX Biotech Limited — Hong Kong, Hong Kong (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.